Notable Quotes
"This is the first combination of a BTK inhibitor plus a BCL-2 inhibitor that we expect will receive FDA approval in the U.S." — Jennifer Brown, presenting AMPLIFY results at ASH 2024
AMPLIFY Trial Principal Investigator; Director, CLL Center, Dana-Farber Cancer Institute
Appears in 1 story
"This is the first combination of a BTK inhibitor plus a BCL-2 inhibitor that we expect will receive FDA approval in the U.S." — Jennifer Brown, presenting AMPLIFY results at ASH 2024